Health News

Axelar AB today announces that the first submitted medical article on the ongoing phase I/II cancer study with AXL1717 has been published in Acta Oncologica.

Read more

Filed under: Pharmacy News
Tags: cancer, Pharmacy

Related posts

• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Æterna Zentaris commences perifosine Phase 3 registration trial (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. Read [...]
  
  
• ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011 (0)
  Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Read more [tags] Pharmacy News [/tags]
  
  
• Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer (0)
  Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Zyflamend shows promise for prostate cancer (0)
  Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer. Read more [tags] Pharmacy News [/tags]